ERBB2 and breast carcinoma: The addition of pertuzumab to trastuzumab and chemotherapy combination regimens has been shown to improve outcomes for patients and is now the standard of care for the (neo)adjuvant treatment of HER2+ breast cancer and the first-line therapy of advanced disease, based on the APHINITY and CLEOPATRA studies.